Navigation Links
Existing drugs may help more breast cancer patients
Date:12/7/2012

n this modest percentage translates into more than 4,000 patients per year.

The study, led by senior author Matthew J. Ellis, MD, PhD, of Washington University, and published online Dec. 7 in the journal Cancer Discovery, analyzed data from eight DNA sequencing studies, which together included about 1,500 patients. Two of the sequencing studies were conducted by The Genome Institute at Washington University, in collaboration with study co-author Elaine R. Mardis, PhD, co-director of the genome institute.

Of the 1,500 patients, 25 were found to have HER2 mutations without gene amplification. Not all mutations appeared to have the same effect, however. After analyzing 13 of the mutations, seven were found to drive cancer growth. In the laboratory analysis, most of these mutations responded well to the anti-HER2 drugs lapatinib and trastuzumab, both approved by the U.S. Food and Drug Administration. Although two of the mutations were resistant to lapatinib in lab tests, they responded well to neratinib, a newer anti-HER2 drug that is currently in phase II clinical trials.

Bose also cautions that some mutations were found to be "silent," meaning they did not drive the tumor's growth and therefore would likely not respond to anti-HER2 drugs.

The study's findings have led directly to the launching of a phase II clinical trial to test whether patients with HER2 mutations (but not the amplification) will benefit from anti-HER2 drugs. The trial will include patients with stage IV breast cancer classified as HER2 negative. Their HER2 genes will be sequenced to look for mutations. If mutations are present, they will be treated with neratinib in addition to the standard treatment they would otherwise receive.

At Washington University, the trial will be led by Cynthia X. Ma, MD, PhD, associate professor of medicine. The other centers participating in the study are the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cance
'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
2. Existing drugs offer new treatment options for high-risk childhood leukemia subtype
3. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
4. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
5. Heart Failure Drugs Put to the Test
6. More New Drugs a Bad Fit With Grapefruit, Study Finds
7. Continued Use of ADHD Drugs May Reduce Criminal Behavior, Study Says
8. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
9. Can breast cancer cells reaction to cancer drugs be predicted?
10. Quick, high-volume test offers fast track in search for Alzheimers drugs
11. Structure of enzyme unravelled providing basis for more accurate design of chemotherapeutic drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Existing drugs may help more breast cancer patients
(Date:6/30/2015)... ... ... On June 26, 2015, Harper’s Bazaar Magazine in an article titled “5 ... not expect to cause acne flare-ups. The list includes pillowcases, cell phones, ... are clogged pores and bacteria and each of the named triggers unexpectedly creates a ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
(Date:6/30/2015)... ... June 30, 2015 , ... From the moment a patient enters the ... incredible care that they receive and the luxury in which they are bathed. ... are proud to offer the same experience, just better! , Their office is a ...
(Date:6/30/2015)... ... June 30, 2015 , ... Allied Anesthesia physicians are ... division volunteered to help provide free outpatient procedures to some of Orange County’s ... Jude Medical Center. , The event was coordinated by AccessOC, which was ...
(Date:6/30/2015)... ... June 30, 2015 , ... CCAR is pleased to announce its ... in Hartford, Willimantic and Bridgeport. This month, staff member Jim Higgins left his ... He is excited to take on this role of organizing peer recovery support ...
Breaking Medicine News(10 mins):Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:The Connecticut Community for Addiction Recovery takes Recovery Coaching to a new level 2
... would be helped by reauthorization of ... Program (SCHIP), WASHINGTON, Sept. 28 "We agree with ... who said, ,Covering,these children is worth every cent," said Dr. ... Hispanic Health, the nation,s leading,Hispanic health advocacy group. "The ...
... for All Children on October 6th, CAMBRIDGE, Mass., ... of Shire plc, the global specialty,biopharmaceutical company, invites families ... on Saturday, October 6th for,"Shire Day" when all children ... granted,free admission. As part of the day, all children ...
... for Easily Accessible, Patient- ... centered Facilities, CLEVELAND, ... officials, with the company of several public,officials including Senators Sherrod Brown ... of a 53-acre,field in Beachwood into a model showcase for 21st ...
... Church Team Up to Transport Goods to Peru, ... today,teamed up with its largest customer, DHL, to provide ... of Jesus Christ of Latter-day,Saints to help those injured ... Peru, on August 15, 2007. The 67,000 pounds of,specially ...
... The Russell,Investment Group has advised Protalix Biotherapeutics ... float weight adjustment effective after the close of,trading ... Russell 2000,Russell 2000 Growth, Russell 2500, Russell 2500 ... Growth, Russell Small Cap,Completeness and the Russell Small ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader in ... announced that it expects,to release its first quarter earnings ... trading hours, and then host a conference call on,Thursday, ... the results. Investors,are invited to participate in this conference ...
Cached Medicine News:Health News:Hispanic Leaders Urge President Bush to Sign SCHIP Bill 2Health News:Families Invited to Celebrate 'Shire Day' at Boston Children's Museum 2Health News:UH to Break Ground for New Ahuja Medical Center 2Health News:UH to Break Ground for New Ahuja Medical Center 3Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 2Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 3Health News:Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment 2Health News:Immucor Schedules First Quarter Earnings Release and Conference Call 2
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored at ... Technology in the Service of Society Award. IEEE President and ... Barry L. Shoop presented the award to Principal Scientist ... ceremony was held Saturday, June 20, 2015, at the historic ... . "I have spent more than 3 ...
(Date:6/29/2015)... Minn. , June 29, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... it has commenced an underwritten public offering of units. ... stock, Series A warrants to purchase common stock and ... purchase of units in the offering would result in ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Daktari Honored with IEEE Spectrum Award 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
... 5 P.M. EDT MONDAY, AUG. 4/, /ADVANCE/ ROCKVILLE, ... should not be,screened for prostate cancer, and younger men ... (PSA) test with their clinicians,before being tested, according to ... The recommendation and accompanying,evidence summary appear in the August ...
... 12 with 48-week boceprevir-based ... combination therapy ... KENILWORTH, N.J., Aug. 4 Schering-Plough,Corporation (NYSE: SGP ) today reported ... boceprevir, its investigational,oral hepatitis C protease inhibitor. The analysis showed a high ...
Cached Medicine Technology:Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 2Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 2Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 4Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 6Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 7Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 8Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: